Community Interviews

1. Please would it be possible to tell us about Myeloma Patients EuropeMyeloma Patients Europe (MPE) is an umbrella organisation of myeloma and AL amyloidosis…

This show will not be live streamed. You can submit your questions in advance by clicking the button "Notify when available." Learn about the latest in…

We conducted a retrospective population-based, matched cohort study using the National Health Insurance Research Database to estimate healthcare resource…

In this ARC TALKS webinar, ARC’s own Kristen Hsu presented the most current updates for the clinical trial landscape, with a focus on ATTR amyloidosis. Kristen will…

A 69-year-old female presented with symptomatic atrial fibrillation. Cardiac amyloidosis was suspected due to an artificial intelligence clinical tool applied to…

Target Audience and Goal StatementThis activity is intended for cardiologists, cardiothoracic surgeons and vascular surgeons, emergency medicine physicians, and…

Cardiac amyloidosis is a great masquerader that often results in misdiagnosis of this condition. Early clinical recognition is crucial for timely therapeutic…

Transthyretin cardiac amyloidosis (ATTR-CA) predominantly affects older adults with multiple chronic conditions, leading to significant physical, cognitive, and…

Intended Audience: Neurologists and cardiologists and the care teamEarly recognition of hereditary amyloid transthyretin (ATTRv) amyloidosis is critical for timely…

Morie A. Gertz, MD, chair, General Internal Medicine, Mayo Clinic Comprehensive Cancer Center, discusses the rationale for the phase 3 AFFIRM-AL trial (NCT04973137…